N8 Medical Announces Michael Triplett Has Assumed the Role of Chief Executive Officer

Share Article

Announcement comes on the first day of the North American Cystic Fibrosis Conference, where the latest data on N8's patented biopharmaceutical will be presented.

N8 Medical, Inc., a biopharmaceutical company commercializing innovative therapeutics and combination devices to address critical unmet needs in infectious disease and oncology, today announced that Michael Triplett, Ph.D. assumed the role of Chief Executive Officer of N8 Medical on September 12, 2013.

Dr. Triplett came to N8 Medical one year ago from Battelle Memorial Institute, where he led Strategic Marketing for the Health & Life Sciences Global Business. Dr. Triplett previously directed strategic planning, business development and commercialization efforts in the Biopharmaceuticals, Medical Devices and Diagnostics business. Before joining Battelle, he worked at both Procter & Gamble and Ventaira Pharmaceuticals in product development and pharmaceutical development capacities.

Dr. Triplett will continue to lead N8 Medical’s development of high value applications for N8 Medical’s patented ceragenin technology, also known as CSAs. Ceragenins are small molecule mimetics of antimicrobial peptides, critical constituents of the human innate immune system. Like antimicrobial peptides, ceragenins possess potent, broad spectrum antimicrobial, anti-inflammatory, and anti-cancer properties without the risk of engendering bacterial resistance.

“When I joined N8, the data portfolio was impressive and the opportunities for application of this technology seemed vast,” said Dr. Triplett, “and while this remains true, this past year’s technical progress and deeper commercial diligence confirmed compelling value propositions in certain rare diseases. With this greater focus, N8 Medical is well positioned to transform the standard of care in certain infectious disease and oncology markets.”

N8 Medical’s lead development project is a novel inhaled antibiotic to treat lung infections in cystic fibrosis patients. Ceragenins have broad-spectrum antimicrobial efficacy against gram-positive and gram-negative bacteria, drug-resistant strains, biofilms, and fungi, including strong activity against most clinical strains deemed most relevant by the Cystic Fibrosis Foundation. Ceragenins have also been shown to retain their activity in environments modeling the lungs of cystic fibrosis patients; where the chemistry of the disease normally deactivates the body’s own defenses, ceragenins continue to fight the infection.

N8 also has preclinical programs underway in anti-biofilm medical devices, multiple myeloma, and oral mucositis. According to the CDC and other government agencies, one of the largest problems in healthcare today is the growing number and severity of hospital-acquired infections (HAIs). Pathogens are developing resistance to pharmaceuticals faster than innovation can make new ones, and according to the latest numbers, as many as 400,000 people die from HAIs each year.

In multiple myeloma, certain ceragenin compounds strongly express the anticancer activity of endogenous antimicrobial peptides, and those have been shown by the National Cancer Institute and subsequent university testing to be highly potent against multiple myeloma and in the reduction of oral mucositis severity.

Former CEO, David J. Richards, who also leads the investment group behind N8 Medical, Empire Advisors, LLC, will remain as Chairman of the Board of Directors, and keep an active role in the company. For more information on the management team, ceragenin technology, or the opportunities of which N8 Medical is currently in pursuit, please visit our website.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ben Davidson
Visit website